Like many biotech companies, The Cambridge, MA-based cancer drug developer, whose shares had slumped after its IPO early last year, has seen its share price spike in recent weeks amid mounting interest in the sector from public investors.
Verastem has changed CEOs as the company seeks to translate stem cell discoveries into powerful new cancer drugs. Biotech entrepreneur and Verastem co-founder Christoph Westphal is stepping down from the chief executive post, and president and COO Robert Forrester will take the top job at the company and join the board of directors on July 1.
Verastem's quest to develop drugs that block cell signaling pathways that cancer stem cells need to survive hits a major milestone in mid-2013, when it launches a 350-patient clinical trial of a potential companion biomarker test for its investigative mesothelioma drug treatment.
Verastem has signed on with LabCorp to validate biomarkers and develop companion diagnostics for VS-6063, the company's in-development mesothelioma treatment.
In a series of rapid-fire press releases over the past 18 hours, cancer drug upstart Verastem vaulted to the threshold of Phase II with an in-licensing deal with Pfizer, announced a development pact with Eisai and ran through a series of highlights for its R&D day review.
A year after scoring a $20 million milestone from Bayer, OncoMed Pharmaceuticals is preparing to see if it can generate enough excitement from investors for its cancer stem cell work to support a $115 million IPO.
Anyone trying to understand what it takes to pull off a successful biotech IPO these days should check out a series of 13Ds Verastem's ($VSTM) insiders filed last month. In the days after...
After burning through more than $122 million, the late-stage osteoporosis drug developer Radius Health is filing to go public in the hope of raising up to $86 million. Radius is betting that it can
Christoph Westphal's Verastem, a preclinical-stage biotech focused on cancer stem cell research, seemingly defied gravity with an announcement late last night that its IPO raised $55 million from the
As today's report on 2011's small class of biotech IPOs makes clear, this is a lousy time for a drug developer to go public--even if it has a compelling late-stage program to boast about. But